Propanc Biopharma, Inc.: Form 10-K for the period ended Jun 30, 2013
Filed with the SEC on Oct 15, 2013 and accepted by EDGAR at Oct 15, 2013, 15:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2012-07-01 to 2013-06-30 | $12.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2012-07-01 to 2013-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2012-07-01 to 2013-06-30 | $5.5k | us-gaap:InterestExpense |
| Income tax | 12 months2012-07-01 to 2013-06-30 | −$60.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2012-07-01 to 2013-06-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2012-07-01 to 2013-06-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2012-07-01 to 2013-06-30 | −$128.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | At period end2013-06-30 | $1.2k | us-gaap:AssetsCurrent |
| Total assets | At period end2013-06-30 | $1.7k | us-gaap:Assets |
| Current liabilities | At period end2013-06-30 | $794.2k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2013-06-30 | −$792.5k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-13-005698. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.